Immunocore Holdings plc
NASDAQ:IMCRBiotechnology
+$0.18 today
- Market cap
- $1.42B
- Beta
- 0.75
- P/E (TTM)
- -77.5
- EPS (TTM)
- -$0.37
Volume 0.30M
Average 0.40M
IMCR Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Immunocore Holdings plcNASDAQ: IMCR
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow dips below year-ago levels
Q1 FY2026 financing cash flow of $654.9K fell 74.3% year over year, behind the +121.3% change in trailing-twelve-month financing cash flow. Sequentially, it fell 84.7% from the prior quarter. Over 3 fiscal years it compounded at -60.2% a year.
Context
- Financing cash flow amounted to 3.1% of revenue in FY2025, down 135.6 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -74.3% toward the trailing-twelve-month pace of +121.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
Mixed currencies · from the cash flow
- Latest · FY2025
- 9.2M USD
- Year-over-year change
- -97.3%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.2M | -97.3% |
| FY2024 | 2024-12-31 | 343.88M | — |
| FY2023 | 2023-12-31 | 27.18M | -81.3% |
| FY2022 | 2022-12-31 | 145.44M | -49.5% |
| FY2021 | 2021-12-31 | 288.19M | — |
Financing Cash Flow vs competitors
How IMCR compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +121.3% is the 4th highest of 10, against a peer median of -16.8%.
- Financing cash flow amounts to 2.7% of revenue for IMCR, versus a peer median of 40.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $376.3M USD | -16.8% | +19.7% | 206.1% | |
| LTM Jun 2026 | $313M USD | +30.4% | +145.5% | 267.5% | |
| LTM Mar 2026 | €118.48M EUR | -17.9% | -8.9% | 317.7% | |
| LTM Jun 2026 | €112.12M EUR | +142.6% | -67.0% | 4.2% | |
| LTM Mar 2026 | $69.59M USD | +16083.5% | +247.3% | 44.3% | |
| LTM Mar 2026 | $10.47M USD | +121.3% | -60.2% | 2.7% | |
| LTM Jun 2026 | $8.3M USD | -95.9% | +13.0% | 7.9% | |
| LTM Mar 2026 | $7.94M USD | -98.0% | +114.7% | 36.7% | |
| FY2025 | €5.83M EUR | +197.0% | — | 209.2% | |
| FY2025 | A$525.12K AUD | -100.6% | — | 10.4% | |
| LTM Dec 2025 | $0 USD | — | +210.9% | 0.0% | |
| Peer median (excluding IMCR) | — | -16.8% | +67.2% | 40.5% | |
Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · GBP | FY2022 Dec 2022 · GBP | FY2023 Dec 2023 · GBP | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (180.03M) | (52.54M) | (34.32M) | (51.09M) | (26.42M) |
| Depreciation & Amortization | 7.59M | 5.34M | 3.24M | 4.2M | 2.43M |
| Deferred Income Tax | (12.69M) | (3.53M) | 0 | 0 | 11M |
| Stock-Based Compensation | 48.89M | 32.89M | 25.69M | 34.19M | 0 |
| Change in Working Capital | (21.96M) | (24.17M) | 4.58M | 45.13M | (6.92M) |
| Accounts Receivables | (4.86M) | (26.26M) | (14.14M) | (12.35M) | (5.46M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.47M | 4.91M | 2.08M | 7.27M | (1.83M) |
| Other Working Capital | (18.57M) | (2.81M) | 16.64M | 50.21M | 366K |
| Other Non-Cash Items | 15.09M | (7.19M) | 3.14M | (6.38M) | 11.94M |
| Operating Cash Flow | (143.11M) | (49.21M) | 2.33M | 26.06M | (7.97M) |
| Capital Expenditures | (1.39M) | (2.2M) | (4.29M) | (5.17M) | (3.23M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (350M) | (22.32M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 13.39M |
| Other Investing Activities | 106K | 6K | (925.46K) | 44K | 0 |
| Investing Cash Flow | (1.28M) | (2.2M) | (4.29M) | (355.13M) | (12.16M) |
| Debt Repayment | 0 | 0 | 0 | 352.5M | 0 |
| Common Stock Issued | 286.89M | 139.52M | 0 | 6.8M | 9.2M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.3M | 5.93M | 27.18M | (15.42M) | 0 |
| Financing Cash Flow | 288.19M | 145.44M | 27.18M | 343.88M | 9.2M |
| Effect of Forex Changes | 625K | (12.65M) | 6.56M | (1.71M) | 19.81M |
| Net Change in Cash | 144.42M | 81.39M | 31.78M | 13.11M | 8.89M |
| Free Cash Flow | (144.49M) | (51.41M) | (1.97M) | 20.89M | (11.2M) |
Immunocore Holdings plc
NASDAQ:IMCR
Intrinsic Alpha fair value
Locked
Current Price
$27.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.